Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 65, Issue 7, Pages 509-515Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2011.06.006
Keywords
Salinomycin; Aldehyde dehydrogenase; Gastric cancer
Funding
- National Natural Science Foundation of China [81172329, 30770961, 30973486]
- Chinese National High Tech Program [863-2006AA02A402, 2006AA02A301]
- Shanghai Science and Technology Commission [09DZ1950101, 09JC1409600]
- Shanghai Excellent Academic Leader Plan [11XD1403600]
Ask authors/readers for more resources
Salinomycin is a novel identified cancer stem cells (CSCs) killer. Higher ALDH activity represents CSCs characterization. Here, we screened ALDH activities on several gastric cancer cell lines and divided them into ALDH(high) and ALDH(low) gastric cancer groups. ALDH(high) cancer cells (NCI-N87 and SNU-1) disclosed more CSCs characteristics, such as higher levels of Sox2, Nanog and Nestin, more floating spheroid bodies, more colony formation and more resistance to conventional chemotherapeutic drugs 5-Fu and CDDP, compared to these parameters observed in ALDH(low) cancer cells (P < 0.01). Importantly, ALDH(high) cancer cells are relatively sensitive to salinomycin when compared to ALDH(low) cancer cells (P < 0.01). Our results confirmed ALDH as functional marker of CSCs population on gastric cancer. Salinomycin might be selective therapy for CSCs fraction, which is resistant to conventional anticancer drugs 5-Fu and CDDP. (C) 2011 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available